PTC Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
For joining us here at the Jefferies Healthcare Conference in London. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us this morning the management team of PTC Therapeutics. I have with me on stage Matt Klein and Pierre Gravier, and we are going to get into some fun topics across Sephience and other things. Matt, can I ask you to kick it off and just give us a quick intro to the company?
Sure, absolutely. Faisal, thank you for having us. Great to be here. PTC is a global rare disease company that has both R&D and commercial capacity. We have a strong global commercial infrastructure, and 2026 has really been a highly successful year for us, led by this continued successful launch of our oral PKU drug, Sephience. Right now, we closed the third quarter with $182 million in revenue, which is, I think, much stronger than anyone expected. This has been a truly global launch, where we launched it in the U.S., Europe, Japan, and will be in over 20 countries by the end of the year. So, that is off to a great start. We also have very strong R&D capabilities in inflammation, metabolism, and neurology, with research in splicing.
We have the leading oral small molecule splicing platform that really pioneered the field and continues to be a source of valuable programs. Also this year, we set as a goal for the company to become cash flow break-even, and we are absolutely on target to achieve that, which puts us in great position next year to start thinking about moving to sustainable profitability. We also remain in a very strong financial position, closing the third quarter with over $2.1 billion in cash.
Got it. Awesome. Thank you for that overview, Matt. I want to get into the nitty-gritty on Sephience. Can you talk to us about the growth trajectory that you have seen on Sephience so far, and just where you sit today, just to kind of frame it up for us, in terms of number of patients that have tried the drug compared to the TAM available here?
Absolutely. Look, by all measures, we are one year into the Sephience launch now, and by all measures, it has been an incredible success. We set out to, as I mentioned in my opening remarks, to have a global launch, be able to access what we see as a significant size population, 17,000 in the U.S., 58,000 including the U.S. and countries worldwide where we believe we can obtain access. We have a highly differentiated therapy in it being oral, having demonstrated the ability to be effective in the full spectrum of patients, regardless of age, regardless of disease severity, and therefore, had a tremendous opportunity to access this entire market.
Got it. We also have global commercial infrastructure, which allowed us to basically plug and play in regions all over the world.
The story of the first year, in addition to the strong performance in revenue, has been breadth. We have been able to early on penetrate all of the key market segments, whether those be those currently on therapies, those who have never tried therapies, or those who have tried and failed existing therapies, as well as the full age range of patients. We shared that by the second full quarter of launch, we already had prescriptions from 100% of the centers of excellence in the U.S. So, that just tells you how early on we really have gotten wide in terms of the patient base, which now allows us to grow significantly from here. I would say we have had great success early on, but we are still very, very early on.
Just take the U.S., for example, where there is an estimated 17,000 patients, and Kuvan, I think the numbers are about 70% of patients tried Kuvan. We know already that we said we have over 2,000 patients globally at this point in time, but we know that we have only begun to penetrate the entire market. If you consider 17,000 patients, even if you are talking about 70% of those patients trying, we still have a long way to go. Then add on top of it that we have been able to penetrate those 30% who did not try Kuvan. This really sets us up to be in position to continue to penetrate all of those segments, and we still expect, as we have said, steady growth in the U.S. as we continue to move forward and penetrate segments.
Outside the U.S., we expect to have continued growth as we bring new markets, as we get access in new markets, which we expect the next growth to come in 2027.
Got it. Matt, it is always hard to keep investors happy, and I guess with this, the flip side of having such a strong kind of white-hot launch out of the gate is that the question then becomes, to what extent can you sustain that? That has been a little bit of the kind of investor controversy on this Yeah especially on the U.S. side, how and if you can sustain the growth clip.
Yeah. Can you just talk about that a little bit?
How should we be thinking about that?
Yeah, 100%. Look, I think we love to look back and say, before we started this launch, most people thought we were going to peak globally at $600 million. We are on a run rate beyond that now, already beyond that in the U.S. alone. I think you have to think about it in several ways. It is hard to imagine a drug with this profile peaking in year one. Also, when you think about the addressable market and how many more patients there is to go in the U.S. So, if you are seeing 17,000 patients in the U.S., just going back to the numbers I mentioned, 17,000 patients in the U.S., 70% of those tried Kuvan. The reason the other 30% did not try Kuvan is because they had mutations that most believe would not respond to Kuvan.
About 25% of our prescriptions so far come from that segment. So, what you are seeing, just look at the numbers. We have got a very long, long way to go in terms of patients trying Kuvan. Absolutely, there was an acceleration out of the gates. That reflects the differentiated profile of the drug, the incredible work our teams did in market development and market penetration. Now we come to this one-year point, and this same team that delivered far beyond anyone's expectations in year one is poised to continue to deliver as we go forward. You basically got a very large pool of patients who have not tried.
You have a track record of success for those who are on the drug, regardless of severity and having benefits in terms of phenylalanine lowering, diet liberalization, neurocognitive benefits, and you have a team that has demonstrated to execute, that has been able to take the lessons from year one and now put in place tailored tactics to ensure that we can continue to penetrate. The benefit of having this breadth of launch and a strong patient base this early is it allows you to make learnings. It allows us to understand on a center-by-center basis, prescriber-by-prescriber basis within each center, understand what we need to do in order to continue to grow at the rate we think we are going to grow. Our commentary has been quite consistent the past few quarters. We expect growth in the U.S. to be steady.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
